Leah Lawrence

Adjuvant canakinumab does not improve disease-free survival in patients with resected non-small cell lung cancer, data suggest.

Patients with advanced Merkel cell carcinoma who have achieved a complete response with avelumab may be able to safely discontinue treatment after 1 year.

Venetoclax plus dexamethasone did not improve progression-free survival over pomalidomide plus dexamethasone in patients with t(11;14)-positive relapsed or refractory multiple myeloma in the phase 3 CANOVA trial.

Researchers have identified first-line treatment regimens that appear to be associated with the best outcomes in advanced, unresectable ESCC.

First-line treatment guided by biomarker testing results improves survival in patients with advanced non-small cell lung cancer, a study suggests.

Using next-generation sequencing to guide treatment is feasible in patients with platinum-refractory head and neck cancer, according to researchers.

A meta-analysis suggests that ranitidine does not pose an increased risk of cancer when compared to other histamine-2 receptor antagonists.

Screening can lead to earlier diagnosis of high-grade serous ovarian cancer, but this does not translate to a substantial improvement in survival, according to researchers.

A meta-analysis that included more than 2.1 million people suggested that recommended cancer screening may not extend patients’ life spans.

Adding tumor-treating fields therapy to standard treatment improves survival in patients with metastatic non-small cell lung cancer, a study suggests.